{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:59:27Z","timestamp":1792483167070,"version":"4.5.0"},"reference-count":35,"publisher":"The Endocrine Society","issue":"5","license":[{"start":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T00:00:00Z","timestamp":1577923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["NIH-P30-AR072577"],"award-info":[{"award-number":["NIH-P30-AR072577"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Discontinuation of denosumab leads to a rapid reversal of its therapeutic effect. However, there are no data regarding how unintended delays or missed injections of denosumab impact bone mineral density (BMD) response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We examined the association of delays in injections of denosumab with BMD change.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>We used electronic medical records from two academic hospitals from 2010 to 2017.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Patients older than 45 years of age and used at least 2 doses of 60 mg denosumab. Denosumab adherence was evaluated by the medication coverage ratio (MCR). Good adherence corresponds to a dosing interval \u22647 months (defined by MCR \u226593%), moderate adherence corresponds to an interval of 7 to 10 months (MCR 75%\u201393%), and poor adherence corresponds to an interval \u226510 months (MCR \u226475%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcome Measures<\/jats:title>\n                    <jats:p>Annualized percent BMD change from baseline at the lumbar spine, total hip, and femoral neck.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 938 denosumab injections among 151 patients; the mean (SD) age was 69 (10) years, and 95% were female. Patients with good adherence had an annualized BMD increase of 3.9% at the lumbar spine, compared with patients with moderate (3.0%) or poor adherence (1.4%, P for trend .002). Patients with good adherence had an annualized BMD increase of 2.1% at the total hip, compared with patients with moderate (1.3%) or poor adherence (0.6%, P for trend .002).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A longer interval between denosumab injections is associated with suboptimal BMD response at both spine and total hip. Strategies to improve the timely administration of denosumab in real-world settings are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgz321","type":"journal-article","created":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T02:57:50Z","timestamp":1577933870000},"page":"1435-1444","source":"Crossref","is-referenced-by-count":36,"title":["Delayed Denosumab Injections and Bone Mineral Density Response: An Electronic Health Record-based Study"],"prefix":"10.1210","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0128-0062","authenticated-orcid":false,"given":"Houchen","family":"Lyu","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Inflammation, and Immunity, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"National Clinical Research Center for Musculoskeletal Diseases, Beijing, China"},{"name":"Department of Orthopedics, General Hospital of Chinese PLA, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sizheng S","family":"Zhao","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Inflammation, and Immunity, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"},{"name":"Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool,, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Inflammation, and Immunity, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara K","family":"Tedeschi","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Inflammation, and Immunity, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Xu","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Inflammation, and Immunity, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar U","family":"Nigwekar","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin Z","family":"Leder","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Endocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H","family":"Solomon","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Inflammation, and Immunity, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2020,1,2]]},"reference":[{"issue":"5","key":"2021122104155102100_CIT0001","doi-asserted-by":"crossref","first-page":"nrd3705","DOI":"10.1038\/nrd3705","article-title":"Bench to bedside: elucidation of the OPG\u2013RANK\u2013RANKL pathway and the development of denosumab","volume":"11","author":"Lacey","year":"2012","journal-title":"Nat Rev Drug Discov."},{"issue":"4","key":"2021122104155102100_CIT0002","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"issue":"8","key":"2021122104155102100_CIT0003","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med."},{"issue":"7","key":"2021122104155102100_CIT0004","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"2021122104155102100_CIT0005","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1530\/EJE-18-0056","article-title":"Therapy of endocrine disease: denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis","volume":"179","author":"Anastasilakis","year":"2018","journal-title":"Eur J Endocrinol."},{"issue":"2","key":"2021122104155102100_CIT0006","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","article-title":"Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial","volume":"43","author":"Miller","year":"2008","journal-title":"Bone."},{"issue":"6","key":"2021122104155102100_CIT0007","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/jbmr.3110","article-title":"Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases","volume":"32","author":"Anastasilakis","year":"2017","journal-title":"J Bone Miner Res."},{"issue":"5","key":"2021122104155102100_CIT0008","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00198-015-3380-y","article-title":"Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports","volume":"27","author":"Aubry-Rozier","year":"2016","journal-title":"Osteoporos Int."},{"key":"2021122104155102100_CIT0009","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","article-title":"Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS","volume":"105","author":"Tsourdi","year":"2017","journal-title":"Bone."},{"issue":"5","key":"2021122104155102100_CIT0010","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1007\/s00198-015-3458-6","article-title":"Rebound-associated vertebral fractures after discontinuation of denosumab\u2014from clinic and biomechanics","volume":"27","author":"Popp","year":"2016","journal-title":"Osteoporos Int."},{"issue":"2","key":"2021122104155102100_CIT0011","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J Bone Miner Res."},{"key":"2021122104155102100_CIT0012","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.bone.2017.12.015","article-title":"Rebound vertebral fracture in the dental chair during a tooth extraction whilst on a treatment holiday from denosumab to avoid ONJ!","volume":"108","author":"Leaney","year":"2018","journal-title":"Bone."},{"issue":"1","key":"2021122104155102100_CIT0013","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11657-017-0351-2","article-title":"Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium","volume":"12","author":"Fahrleitner-Pammer","year":"2017","journal-title":"Arch Osteoporos."},{"issue":"4","key":"2021122104155102100_CIT0014","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s00198-016-3886-y","article-title":"Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years","volume":"28","author":"Modi","year":"2017","journal-title":"Osteoporos Int"},{"issue":"10","key":"2021122104155102100_CIT0015","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1007\/s00198-015-3164-4","article-title":"Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study","volume":"26","author":"Hadji","year":"2015","journal-title":"Osteoporos Int."},{"issue":"6","key":"2021122104155102100_CIT0016","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1007\/s00198-010-1378-z","article-title":"Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate","volume":"22","author":"Kendler","year":"2011","journal-title":"Osteoporos Int."},{"issue":"1","key":"2021122104155102100_CIT0017","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00198-011-1780-1","article-title":"Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women","volume":"23","author":"Freemantle","year":"2012","journal-title":"Osteoporos Int."},{"key":"2021122104155102100_CIT0018","doi-asserted-by":"crossref","first-page":"7903128","DOI":"10.1155\/2016\/7903128","article-title":"The Effects of noncompliance to prolia (denosumab) on the changes in bone mineral density: a retrospective review","volume":"2016","author":"Wong-Pack","year":"2016","journal-title":"J Osteoporos."},{"key":"2021122104155102100_CIT0019","article-title":"Delayed denosumab injections and bone mineral density response: an electronic health record-based study, supplement 1","author":"Lyu","year":"2019","journal-title":"figshare"},{"issue":"1","key":"2021122104155102100_CIT0020","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","article-title":"Medication compliance and persistence: terminology and definitions","volume":"11","author":"Cramer","year":"2008","journal-title":"Value Health."},{"key":"2021122104155102100_CIT0021","article-title":"Delayed denosumab injections and bone mineral density response: an electronic health record-based study, supplement 2","author":"Lyu","year":"2019","journal-title":"figshare"},{"issue":"11","key":"2021122104155102100_CIT0022","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care."},{"issue":"9","key":"2021122104155102100_CIT0023","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1002\/jbmr.2202","article-title":"Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011","volume":"29","author":"Solomon","year":"2014","journal-title":"J Bone Miner Res."},{"issue":"4","key":"2021122104155102100_CIT0024","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/aje\/kwf215","article-title":"Statistical analysis of correlated data using generalized estimating equations: an orientation","volume":"157","author":"Hanley","year":"2003","journal-title":"Am J Epidemiol."},{"issue":"19","key":"2021122104155102100_CIT0025","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med."},{"issue":"18","key":"2021122104155102100_CIT0026","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med."},{"issue":"13","key":"2021122104155102100_CIT0027","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","article-title":"The effects of parathyroid hormone, alendronate, or both in men with osteoporosis","volume":"349","author":"Finkelstein","year":"2003","journal-title":"N Engl J Med."},{"issue":"8","key":"2021122104155102100_CIT0028","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N Engl J Med."},{"key":"2021122104155102100_CIT0029","article-title":"Delayed denosumab injections and bone mineral density response: an electronic health record-based study, supplement 3","author":"Lyu","year":"2019","journal-title":"figshare"},{"key":"2021122104155102100_CIT0030","article-title":"Delayed Denosumab injections and bone mineral density response: an electronic health record-based study, supplement 4","author":"Lyu","year":"2019","journal-title":"figshare"},{"issue":"5","key":"2021122104155102100_CIT0031","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1210\/jc.2018-02236","article-title":"Comparison of denosumab vs. bisphosphonates in osteoporosis patients: a meta-analysis of randomized controlled trials","volume":"104","author":"Lyu","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2021122104155102100_CIT0032","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/jbmr.3641","article-title":"Change in bone density and reduction in fracture risk: a meta-regression of published trials","volume":"34","author":"Bouxsein","year":"2019","journal-title":"J Bone Miner Res."},{"key":"2021122104155102100_CIT0033","article-title":"Role of cortical and trabecular bone architecture in osteoporosis.","author":"Wehrli","year":"2009"},{"key":"2021122104155102100_CIT0034","doi-asserted-by":"crossref","first-page":"16069","DOI":"10.1038\/nrdp.2016.69","article-title":"Postmenopausal osteoporosis","volume":"2","author":"Eastell","year":"2016","journal-title":"Nat Rev Dis Primers."},{"key":"2021122104155102100_CIT0035","article-title":"Delayed denosumab injections and bone mineral density response: an electronic health record-based study, supplement 5","author":"Lyu","year":"2019","journal-title":"figshare"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgz321\/31673102\/dgz321.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/105\/5\/1435\/41828984\/jcem_105_5_1435.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/105\/5\/1435\/41828984\/jcem_105_5_1435.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T23:17:44Z","timestamp":1640042264000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/105\/5\/1435\/5693392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,2]]},"references-count":35,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,1,2]]},"published-print":{"date-parts":[[2020,5,1]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgz321","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,5]]},"published":{"date-parts":[[2020,1,2]]}}}